Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tricaprylin
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Tricaprilin, also known as CER-0001, is a specific medium chain triglyceride that Cerecin is developing for a range of neurological indications including Alzheimer’s disease, migraine and infantile spasms.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tricaprylin
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
Tricaprilin, is an investigational oral drug version of a medium chain triglyceride, which has been designed to induce ketosis and thereby improve mitochondrial metabolism.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Levodopa
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
LiberaTx, an NTU-incubated start-up is now commercialising new slow-release pill that delivers L-dopa over a period of 24 hours, which could help to alleviate symptoms related to Parkinson’s disease.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
